Evaluating products.

The form and dose the chromium literature was built on: picolinate is the most-trialed form (the absorption-engineered chemistry of the 1980s), and 200–1000 mcg daily is the studied range — with the honest frame attached: 500 mcg is roughly 15–20× the adequate intake (25–35 mcg), a PHARMACOLOGIC dose, not a nutritional correction, and the trials' mixed verdicts are the ceiling of what the bottle can promise. The evidence grading this page carries: one positive landmark (the 1997 China trial, never replicated at scale), mixed metas, a Cochrane null for type 2 diabetes, and trivial weight effects — a 'maybe, adjunct-tier, behind prescription care' mineral, honestly labeled. 🚨 The interaction set: additive glucose-lowering with diabetes medications (physician conversation before the first tablet); absorption reduced by antacids, acid suppressors, and corticosteroids. No upper limit is established — absence of data, not proof of safety. The picolinate DNA-damage question of the late 1990s (in-vitro, high-dose cell studies) was never substantiated in human use at studied doses — retired below with its history.